Condition: Palmoplantar Pustulosis · Sponsor: LEO Pharma
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.
This description comes directly from the study's public registry record.
Clinical Disclosure · (+45) 4494 5888 · disclosure@leo-pharma.com
Always discuss trial participation with your own doctor first.
| LEO Pharma Investigational Site | Fountain Valley, California, United States | Recruiting |
| LEO Pharma Investigational Site | Douglasville, Georgia, United States | Recruiting |
| LEO Pharma Investigational Site | West Bloomfield, Michigan, United States | Recruiting |
| LEO Pharma Investigational Site | Elmhurst, New York, United States | Recruiting |
| LEO Pharma Investigation Site | Mayfield Heights, Ohio, United States | Recruiting |
| LEO Pharma Investigational Site | Portland, Oregon, United States | Recruiting |
| LEO Pharma Investigational Site | Philadelphia, Pennsylvania, United States | Recruiting |
| LEO Pharma Investigational Site | Calgary, Alberta, Canada | Recruiting |
| LEO Pharma Investigational Site | Surrey, British Columbia, Canada | Recruiting |
| LEO Pharma Investigational Site | Winnipeg, Manitoba, Canada | Recruiting |
| LEO Pharma Investigational Site | Fredericton, New Brunswick, Canada | Recruiting |
| LEO Pharma Investigational Site | Hamilton, Ontario, Canada | Recruiting |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07013201